Interesting how the two studies (www.nejm.org/doi/full/10....) @nejm.org were very similar but powered very differently. Hopefully an planned IPMA will come next but I'd say the writing is on the wall for EPO. Where next, melatonin? @ebneo.bsky.social
Trial of Erythropoietin for Hypoxic–Ischemic Encephalopathy in Newborns | NEJM
Neonatal hypoxic–ischemic encephalopathy is an important cause of death as well as long-term disability in survivors. Erythropoietin has been hypothesized to have neuroprotective effects in infants...
nejm.org
Similar to the HEAL trial, the PAEAN trial in @jamapediatrics.com found no difference in EPO + TH vs TH alone in the reduction of death or disability in newborns with HIE. jamanetwork.com/journals/jamap… #EBNEOalerts #neoEBM #neoSky